AYTU (Aytu BioPharma) Cyclically Adjusted Book per Share: $583.06 (As of Mar. 2026)


AYTU Aytu BioPharma Inc AYTU
40 GF Score
Price $2.16
GF Value $0.84
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Aytu BioPharma Cyclically Adjusted Book per Share?

Aytu BioPharma AYTU +0.47% 40 Cyclically Adjusted Book per Share is $583.06 as of Mar. 2026. GuruFocus rates AYTU with a GF Score™ of 40/100 and a GF Value™ of $0.84 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Aytu BioPharma's adjusted book value per share for the three months ended in Mar. 2026 was $3.274. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $583.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Aytu BioPharma's average Cyclically Adjusted Book Growth Rate was -8.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -11.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Aytu BioPharma was -11.90% per year. The lowest was -30.90% per year. And the median was -14.70% per year.

As of today (2026-07-03), Aytu BioPharma's current stock price is $2.16. Aytu BioPharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $583.06. Aytu BioPharma's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Aytu BioPharma was 3.56. The lowest was 0.01. And the median was 0.14.


Aytu BioPharma  (NAS:AYTU) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aytu BioPharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.16/583.06
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Aytu BioPharma was 3.56. The lowest was 0.01. And the median was 0.14.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Aytu BioPharma Cyclically Adjusted Book per Share Related Terms


Aytu BioPharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Aytu BioPharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aytu BioPharma Cyclically Adjusted Book per Share Chart

Aytu BioPharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,031.41 911.00 783.78 692.56 622.73

Aytu BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 637.24 622.73 608.12 588.92 583.06

AYTU vs TXMD, CPHI, RMTI: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aytu BioPharma Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's Cyclically Adjusted PB Ratio falls into.


AYTU
40GF Score
Aytu BioPharma Inc AYTU
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aytu BioPharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aytu BioPharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.274/330.2130*330.2130
=3.274

Current CPI (Mar. 2026) = 330.2130.

Aytu BioPharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 6,353.000 246.819 8,499.521
201712 3,031.000 246.524 4,059.952
201803 1,416.667 249.554 1,874.552
201806 1,491.667 251.989 1,954.720
201809 1,125.556 252.439 1,472.329
201812 375.434 251.233 493.459
201903 250.578 254.202 325.505
201906 80.545 256.143 103.837
201909 25.822 256.759 33.209
201912 164.317 256.974 211.148
202003 170.384 258.115 217.977
202006 151.057 257.797 193.489
202009 144.774 260.280 183.672
202012 126.055 260.474 159.805
202103 122.038 264.877 152.141
202106 100.049 271.696 121.597
202109 80.274 274.310 96.633
202112 70.310 278.802 83.275
202203 36.657 287.504 42.102
202206 22.969 296.311 25.597
202209 17.272 296.808 19.216
202212 13.543 296.797 15.068
202303 10.823 301.836 11.841
202306 7.134 305.109 7.721
202309 5.817 307.789 6.241
202312 5.901 306.746 6.352
202403 5.527 312.332 5.843
202406 4.640 314.175 4.877
202409 4.851 315.301 5.080
202412 4.986 315.605 5.217
202503 5.656 319.799 5.840
202506 2.113 322.561 2.163
202509 2.338 324.800 2.377
202512 1.323 324.054 1.348
202603 3.274 330.213 3.274

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $583.06 mean?
Aytu BioPharma (AYTU) has a Cyclically Adjusted Book per Share of $583.06 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Aytu BioPharma and its competitors.
Is Aytu BioPharma's Cyclically Adjusted Book per Share too high?
Aytu BioPharma's current Cyclically Adjusted Book per Share is $583.06. Overall, Aytu BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Cyclically Adjusted Book per Share compare to TXMD and CPHI?
Aytu BioPharma's Cyclically Adjusted Book per Share of $583.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Aytu BioPharma and its competitors. Aytu BioPharma's current Cyclically Adjusted Book per Share is $583.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.84, compared to a current price of $2.16 — trading 157.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is $583.06. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current Cyclically Adjusted Book per Share is $583.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aytu BioPharma (AYTU) Overvalued in 2026?

Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued. The current stock price of $2.16 is trading 157.1% above its estimated GF Value™ of $0.84. GuruFocus considers Aytu BioPharma to be Significantly Overvalued.

Key valuation signals for AYTU:

  • Cyclically Adjusted Book per Share: $583.06
  • GF Value™: $0.84 vs. price of $2.16 (157.1% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aytu BioPharma Business Description

Address 7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score

Get the complete analysis for AYTU

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price
$0.84
GF Value